Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

75%

6 of 8 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

4(44.4%)

Phase 1

3(33.3%)

Phase 3

2(22.2%)

9Total

Phase 2(4)

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03931941Phase 3Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Role: lead

NCT03244644Phase 3Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Role: lead

NCT04155099Phase 2Terminated

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

Role: collaborator

NCT03439982Phase 1Completed

Fecal Transplant for Hepatic Encephalopathy

Role: collaborator

NCT03367910Phase 1Completed

Fecal Microbiota Transplantation (FMT) for MDRO UTI

Role: collaborator

NCT02589847Phase 2Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Role: lead

NCT02299570Phase 2Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Role: lead

NCT02981316Phase 1Completed

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Role: collaborator

NCT01925417Phase 2Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

Role: lead

All 9 trials loaded